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Abstract
Background: Alcohol and substance use results in significant human and economic cost globally and is associated
with economic costs of £21 billion and £15billion within the UK, respectively, and trends for use are not improving.
Pharmacological interventions are well researched, but relapse rates across interventions for substance and alcohol use
disorders are as high as 60–90%. Physical activity may offer an alternative or adjunct approach to reducing rates of
alcohol and substance use that is associated with few adverse side effects, is easily accessible, and is potentially
cost-effective. Through psychological, behavioural, and physiological mechanisms, physical activity may offer benefits in
the prevention, reduction, and treatment of alcohol and substance use across the lifespan. Whilst physical activity is
widely advocated as offering benefit, no systematic review exists of physical activity (in all forms) and its effects on all
levels of alcohol and substance use across all ages to help inform policymakers, service providers, and commissioners.
Methods: The objectives of this mixed methods systematic review are to describe and evaluate the quantitative and
qualitative research obtained by a diverse search strategy on the impact of physical activity and its potential to:
1. Reduce the risk of progression to alcohol and/or substance use (PREVENTION)
2. Support individuals to reduce alcohol and/or substance use for harm reduction (REDUCTION), and
3. Promote abstinence and relapse prevention during and after treatment for an alcohol and/or substance use
disorder (TREATMENT).
With the input of key stakeholders, we aim to assess how what we know can be translated into policy and practice.
Quantitative, qualitative, service evaluations, and economic analyses will be brought together in a final narrative
synthesis that will describe the potential benefits of physical activity for whom, in what conditions, and in what form.
Discussion: This review will provide details of what is known about physical activity and the prevention, reduction,
and treatment of alcohol and/or substance use. The synthesised findings will be disseminated to policymakers, service
providers, and commissioners in the UK.
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Background
Rationale
Alcohol and substance use is common: globally, 5.9%
and 1% of deaths are attributable to alcohol and illicit
drug use, respectively [1]. In the UK, alcohol use is at-
tributed to more than one in five deaths of men aged
16–54 years old [2], and alcohol harms are associated
with an economic annual cost of around £21 billion
(£3.5billion in healthcare [3]). Illicit drug use in the UK
has an economic cost of around £15 billion [4] (£488
million through healthcare [5]), with nearly one in ten
adults aged 16–59 in England and Wales having used
illicit drugs in the past year [6]. Worldwide, alcohol-
attributable deaths increased from 3.8% in 2004 [1] to
5.9% in 2012 [7], and illicit drug use levels have failed to
decline between 2005 and 2010 [8], with a slight increase
in the UK in recent years [6].
Scope for identifying new interventions
Pharmacological interventions for alcohol and substance
use disorders have been well researched and reported on
for the management of withdrawal, dependence, and re-
lapse prevention. The Cochrane Drug and Alcohol
Group has published 11 and 30 reviews of pharmaco-
logical interventions for alcohol and substance use, re-
spectively, whilst psychosocial interventions (e.g. brief
interventions and motivational interviewing) are less
well reported, with six and eight published reviews, re-
spectively. Preventive interventions only have five re-
views for alcohol use, and three reviews for substance
use [9]. Due to the heterogeneity of the types of drugs
used and style of intervention, it is hard to summarise
meaningfully the available data of existing interventions.
However, with relapse rates as high as 60% 1 year after
treatment for substance use disorders (SUD) [10–12]
and 60–90% for alcohol use disorders (AUD) [13–16]
and drug substitution therapies being associated with in-
nate complications [17–20], there is a need for evidence
for new treatments and preventive interventions to help
address the growing burden of alcohol and/or substance
use.
Physical activity (PA; defined as any bodily movement
produced by skeletal muscles that requires energy ex-
penditure, inclusive of organised sport [21]) and health-
oriented exercise interventions could impact on the pre-
vention, reduction, and treatment of alcohol and/or sub-
stance use and have the potential to be cost-effective,
flexible, accessible, acceptable across the range of levels
of use and have a lower risk of adverse events compared
to pharmacological treatment [22]. In 2001 (with up-
dates in 2005 and 2008), AT (with co-researchers)
reviewed and reported the effects of exercise on smoking
from eight randomised controlled trials (RCTs) as part
of a Cochrane Review [23]. This evidence contributed to
a 2008 report to the US Surgeon General on smoking
cessation which highlighted the value of exercise as an
option to support smoking cessation [24], and in the
UK, many NHS Stop Smoking Services now advocate
exercise [25]. In 2014, an update to the Cochrane Review
revealed there were 20 RCTs of exercise and smoking
cessation, suggesting a rapid growth of interest in the
topic [23]. A first systematic review is now needed of
physical activity interventions for the prevention, reduc-
tion, and treatment of alcohol and/or substance use that
also includes a comprehensive search of grey literature
and service evaluations to generate practical implications
for practice and policy.
Evidence for the role of PA for preventing alcohol and/or
substance use
Prospective studies indicate that sports participation in
adolescents and young people is associated with an in-
crease in alcohol use but decrease in illicit drug use [26].
However, such studies may fail to eliminate confounding
factors (e.g., specific sports may attract those more pre-
disposed to engaging in ‘risky’ behaviours).
In contrast, a rigorous study in Finland tracked 1870
twin pairs from 16 to 27 years of age and concluded that
low levels of physical activity increased the risk of both
alcohol and illicit drug use [27]. This further demon-
strates the need for a robust, systematic review assessing
the role of physical activity (not just participation in
sports) on progression to alcohol and/or substance use
disorders.
Evidence for the effects of PA interventions for harm
reduction and treatment of alcohol and/or substance use
There is increasing interest in the role of physical activ-
ity as a treatment and reduction strategy for alcohol
and/or substance use. In 2011, the US National Institute
on Drug Abuse (NIDA) invested $4.3 million [28] on a
programme of work including high-quality RCTs such as
STRIDE [29] which is investigating stimulant use reduc-
tion using exercise. A recent systematic review by Wang
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et al. [30] was limited by an incomplete search strategy
(e.g., not CINAHL) and thus omitted key papers. They
identified three studies with a focus on alcohol, five with
a focus on illicit drug use, four on multiple drug use,
and 11 on smoking. The data from each of these studies
were pooled using meta-analysis, despite considerable
apparent heterogeneity across interventions and out-
comes. Harm-reduction studies were not considered. In
another systematic review, Zschucke and colleagues [31]
found nine studies reporting the effects of PA on AUD
and eight on SUD, but again, that review did not include
key search engines and did not consider grey literature
that may be most informative for the UK context. Both
these reviews focussed on AUD and SUD and did not
consider the broader spectrum of use that may not meet
the classification of a disorder, e.g. recreational use that
is still associated with risk of harm. A rigorous review of
the evidence encompassing all aspects of alcohol and
substance use is still needed.
Plausible mechanisms for the effects of exercise on the
use of any addictive substance
Physical activity may affect alcohol and/or substance use
through various psychological mechanisms, such as an
acute reduction in cravings and urges, an increase in
positive affect, and a chronic improvement in co-morbid
depression and anxiety which may moderate outcomes
related to alcohol and substance use [32]. From the be-
havioural perspective, exercise involvement may help
avoidance of cues which trigger cravings and relapse,
and provide exposure to new environments, which pro-
vide diversionary safe and immediately rewarding experi-
ences [32]. Participation in meaningful structured
activities are a key part of overcoming AUD and SUD,
and some physical activities may offer the chance for
identity transformation through exposure to meaningful
routine activities, informal social controls, and promoted
personal agency [33]. From the physiological perspective,
there is evidence from animal studies to suggest that
neurobiological changes associated with exercise [32, 34,
35] help to explain the consistent evidence that exercise
acutely reduces consumption of cocaine, morphine,
nicotine, and alcohol [34, 36–39].
Finally, recent studies indicate that physical activity in-
terventions can be acceptable for those with AUD and
SUD [40–42], but no review exists of this published and
grey literature to help inform the design of the most
feasible and acceptable interventions across the
spectrum of levels of use.
PA may influence alcohol and/or substance use in
similar ways and through common mechanisms and
therefore form the focus of this review. However, due to
the different way in which alcohol and substance use are
viewed, approached, and treated within the UK, they will
be considered separately within this review and not
combined in any analyses in order to ensure the most
pertinent findings for policy and practice.
Impact of stakeholder engagement
Stakeholder engagement has many benefits and can con-
tribute towards the development of systematic reviews.
Stakeholders can be funders, service users, healthcare
professionals, or charities, i.e. anyone who will imple-
ment interventions based on the findings of the reviews.
A research white paper looking at the benefits of stake-
holder engagement in systematic reviews was published
by Cottrell and colleagues in 2014 [43]. They reviewed
papers and suggested that the benefits of stakeholder en-
gagement included identifying and prioritising potential
research topics, helping to recruit participants, and pro-
viding useful feedback on the systematic review protocol.
Other benefits included helping the researchers to
understand the perspective of the service users/partici-
pants and ensuring the accessibility of the results with
wider dissemination. Most studies reviewed were in the
UK, and they suggested that the scope for the reviews
was refined due to stakeholder engagement and that
generally the overall quality of the review was improved.
Given the broad focus of this review across several sec-
tors and service providers in what is an under-
researched area, involving stakeholders will maximise
the applicability and impact of the findings.
As part of this process, our original questions were based
on concerns highlighted by the Plymouth City Council
Public Health team and the Plymouth NHS Hospital Trust
due to the high national prevalence of alcohol and/or sub-
stance use and resulting hospital admissions in the area.
We worked with a local third sector organisation which
provides day support for persons in the community af-
fected by the use of drugs and/or alcohol, as well as an
education service as an alternative to pupil referral units in
Plymouth. Stakeholder groups within this service (three
service providers and eight service users) supported the
focus on our three key research questions about preven-
tion, harm reduction, treatment and relapse prevention,
and highlighted the importance of PA through their own
narratives, independent of, and in addition to, standard
treatment. Further engagement with co-applicants Gary
Wallace (Senior Specialist Drugs and Alcohol Team Man-
ager in the Plymouth Public Health), Julia Sinclair (Honor-
ary Consultant in Alcohol Liaison and Wessex Alcohol
(AHSN) Lead), Joanne Neale (lead for PPI addiction re-
search group at KCL), and local third sector leaders refined
the scope and methods for the review. In addition, co-
applicants Adrian Taylor and Joanne Neale have previously
conducted and published qualitative research involving
people with SUD which highlighted the need to further de-
velop appropriate interventions [25, 42]. The scope and
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methods for this review have been strongly influenced by
both service provider and user perspectives throughout the
development of the application and this protocol.
Aim and objectives
Our overarching aim is to describe and evaluate the quan-
titative and qualitative research on the impact of physical
activity on the prevention, reduction, and treatment of al-
cohol and/or substance use across the lifespan.
Physical activity interventions (including those involv-
ing sport, exercise, or general lifestyle physical activity)
may have the potential to impact three domains of alco-
hol and/or substance use:
1. Reduce the risk of progression to alcohol and/or
substance use (PREVENTION);
2. Support individuals to reduce alcohol and/or substance
use for harm reduction (REDUCTION), and
3. Promote abstinence and relapse prevention during
and/or after treatment of AUD and SUD
(TREATMENT).
We aim to describe and evaluate the available quantita-
tive and qualitative research for each of these scenarios and
seek to assess how what we know can best be translated
into policy and practice with the input of key stakeholders,
presenting where possible any cost-effectiveness data.
This will be achieved by the following objectives:
a) To quantify and describe quantitative data relating
to the impact of physical activity on alcohol and/or
substance use outcomes (completing meta-analyses
where possible);
b) To analyse and describe qualitative data relating to
the acceptability, feasibility, mechanisms, mediators,
and moderators of physical activity in relation to
alcohol and/or substance use (completing meta-
syntheses where possible);
c) To describe and analyse service evaluations which
may not meet peer-reviewed quantitative or qualita-
tive inclusion criteria relating to the implementation
and impact of physical activity interventions relating
to alcohol and/or substance use;
d) To quantify and describe potential cost-effectiveness
data relating to physical activity and its impact on al-
cohol and/or substance use;
e) To produce practical recommendations about what
is known about what works for who, when, where,
and how through a narrative synthesis informed by
stakeholder input.
Each of these objectives will address the three domains
of prevention, reduction, and treatment, separately, but
some crossover will be expected.
Table 1 Outcomes tabled by population, intervention, control, and outcome against the three domains of physical activity and its
possible impact on alcohol and substance use
(1) Prevention (2) Reduction Treatment (and relapse prevention)
Population Adolescents, at risk groups General population who use alcohol or
substances but not receiving acute or
long-term care for a diagnosed AUD and/
or SUD, at risk groups
Those receiving/have received acute or
long-term care for a diagnosed AUD and/
or SUD
Intervention Sport and physical activity-based pro-
grammes (schools, community, public
health interventions)
Public health level initiatives, targeted
community- and healthcare-based
interventions
Adjunct PA interventions, prescribed and
supported PA interventions, motivational
interventions
Control Other non-PA control, usual care, or no
intervention
Other non-PA control, usual care, or no
intervention
Standalone usual care, non-PA control
Outcome
(a)
Quantitativea
Levels of subsequent use of alcohol and/
or substances, prevalence rates
% reduction in alcohol and/or substance
use, prevalence
Abstinence rates, % days abstinent, %
reduction in alcohol and/or substance use,
relapse rates
(b)
Qualitative
Acceptability, feasibility, barriers and
facilitators of PA
Acceptability, feasibility, barriers and
facilitators of PA, perceived utility of PA
Acceptability, feasibility, barriers and
facilitators of PA, perceived utility of PA
(c) Service
Evaluations
Mixture of above (a) and (b) outcomes,
implementation issues
Mixture of above (a) and (b) outcomes,
implementation issues
Mixture of above (a) and (b) outcomes,
implementation issues
(d)
Economic
Costs, cost-effectiveness, net benefit, re-
source use and cost, economic measures
of benefit (e.g. Quality-adjusted-life-years
(QALYs), and willingness to pay (WTP)),
summary economic measures (e.g. incre-
mental cost-effectiveness ratios ICERs)
Costs, cost-effectiveness, net benefit, re-
source use and cost, economic measures
of benefit (e.g. Quality-adjusted-life-years
(QALYs), and willingness to pay (WTP)),
summary economic measures (e.g. incre-
mental cost-effectiveness ratios ICERs)
Costs, cost-effectiveness, net benefit, re-
source use and cost, economic measures
of benefit (e.g. Quality-adjusted-life-years
(QALYs), and willingness to pay (WTP)),
summary economic measures (e.g. incre-
mental cost-effectiveness ratios ICERs)
aOutcomes listed are indicative and not exhaustive
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Methods
This protocol has been prepared using the Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses protocols (PRISMA-P) guidelines [44] (see
Additional file 1).
Eligibility criteria
We will not limit our searches by country; however, we
will only include papers published in English. Whilst we
recognise there is a potential for bias to be introduced
because of limiting the searches to English, the direction
and degree of such bias are unknown. As outlined in the
Cochrane Handbook for Systematic Reviews of Interven-
tions [45], there is conflicting evidence about the poten-
tial bias introduced by an English language limit: Juni
[46] reported that non-English trials were more likely to
report significant results, whilst Moher [47] reported no
significant difference in meta-analyses which excluded
trials in languages other than English. Studies will be re-
stricted from 1978 to the present: 1978 was chosen as a
cutoff point based on a frequency analysis on a sub-
sample of relevant literature.
Types of studies
We will include (a) quantitative studies (RCTs, quasi-
RCTs, non-randomised controlled trials, controlled be-
fore and after studies, prospective or retrospective co-
hort studies that include a control group, historically
controlled trials, nested case-control studies, case-
control studies, and before-and-after comparisons); (b)
qualitative investigations (of any recognised qualitative
methodology); (c) local service evaluations; and (d) eco-
nomic evaluations (full and partial).
Type of setting
We will not limit the setting or country in which inter-
ventions are delivered (although this will be impacted
considerably by the English language restriction), and
this variation will be considered in the narrative synthe-
sis. Studies may include inpatient and outpatient pro-
grammes, public health interventions, and community-
based interventions. We will not place any limitations
on who delivers the intervention and in what format.
Participants/population
No limit on participants will be applied; all adults and
children will be considered. We expect most studies to
include adolescents at risk of alcohol and substance use
(prevention), adults in acute rehabilitation for SUD/
AUD and post-acute rehabilitation for SUD/AUD (re-
lapse prevention and supporting abstinence), and any
other adults receiving support or intervention for redu-
cing alcohol and substance use (reduction). We will rec-
ord and consider these diversities in the synthesis of
results. We expect certain populations to be of particular
significance in the research (e.g. people who are home-
less, have mental health problems, or belong to groups
experiencing complex needs or disadvantages), where al-
cohol and substance use may not be the primary out-
come and physical activity may be part of a more
complex intervention. Where this type of study is identi-
fied, it will be assessed for relevance on a case-by-case
basis, discussed within the research team, and included
if it contains viable data that can be included within the
review’s defined primary outcomes.
Intervention(s) and comparator(s)
We will include any studies evaluating and comparing
interventions that include a physical activity promotion
element either explicitly targeting a reduction in alcohol
and substance use or implicitly resulting in a reduction
in alcohol and substance use. This could be within one
of the three domains of prevention, reduction, or treat-
ment. The comparator could be no intervention, treat-
ment as usual (e.g. pharmacotherapy and psychological
therapies), or alternative physical activity interventions
(e.g. running vs walking).
The scope of this review is to include research on al-
cohol and substance use in its broadest sense. We plan
to include data on alcohol and substance use which may
not be considered a ‘disorder’ which reflects levels and
prevalence of use, as well as including research on AUD
and SUD as classified in the diagnostic and statistical
manual of mental health disorders, fifth edition (DSM-
V) [48].
Outcomes
The primary outcomes are mapped against the four
planned analyses by the three domains of PA and its
possible impact on alcohol and/or substance use in
Table 1.
Secondary outcomes
Secondary outcomes will be collected during the data
extraction phase in addition to the primary outcomes
above where present. These include:
 Physical activity levels/fitness;
 Biomedical outcomes (e.g. liver function, hepatitis C
status);
 Mental health and wellbeing;
 Adverse events.
We will also extract data referring to the identification
of the underlying psychological theory informing inter-
ventions; intervention structure and content; informa-
tion relating to how an intervention may work including
challenges, barriers, and facilitators of behaviour change
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(process evaluations); the mechanisms of change (media-
tors and moderators), acceptability, and feasibility data;
and any evidence of a dose-response relationship.
Information sources
We will develop and test a highly sensitive search strat-
egy of published and grey literature using background
scoping searches, previously identified relevant research,
and in consultation with subject experts and public and
patient involvement. The strategy will include searches
of the following sources:
Database searching
 MEDLINE (Ovid)
 MEDLINE (PubMed)
 Embase (Ovid)
 PsycINFO (Ovid)
 Cochrane Library (Wiley) (including Cochrane
Database of Systematic Reviews, Cochrane Central
Register of Controlled Trials, Database of Abstracts
of Reviews of Effects, Health Technology
Assessment Database, and NHS Economic
Evaluation Database)
 International Bibliography of the Social Sciences
(ProQuest)
 Web of Science Core Collection
 CINAHL (EBSCO)
 AMED (EBSCO)
 Social Policy and Practice (Ovid)
 Applied Social Sciences Index and Abstracts
(ProQuest)
 SocINDEX (Ebsco)
 SportDiscus (Ebsco)
Supplementary database searches
 Google and Google Scholar
 Open Grey
 ProQuest Dissertations & Theses
 British Library EThOS
 Scottish Addiction Studies online library
 HRB National Drugs Library
 NIDA International Drug Abuse Research Abstract
Database
 Tufts CEA Registry
 Database of promoting health effectiveness reviews
(DoPHER)
 NHS Evidence (NICE)
 Big Lottery Fund Database
Search strategy
An Information Specialist (AW) will design and conduct
the search strategy with expert consultation. The
strategy will be translated for use in each database stated
above, and a modified keyword-only strategy will be
used for grey literature searching. The search strategy
will be designed to encompass the three aims of the re-
view (i.e. prevention, reduction, and treatment).
See Appendix 1 for a sample search strategy.
Searching other resources
Extensive grey literature searching will be conducted to
ensure maximum coverage of the subject area. The grey
literature strategy will encompass focused searches in
Google, several specialised databases, and consultation
of subject experts for recommendations. This process
will generate grey literature publications as well as rele-
vant websites of local and national organisations in the
UK, which will be hand-searched for additional citations.
We will also conduct backwards and forwards citation
chaining of all included studies to identify further rele-
vant articles, as well as directly contact-known experts
in the field and the lead authors of key publications for
knowledge of any other relevant work. We will include
PhD theses, but exclude MSc theses.
All grey literature websites and search engines will be
searched with targeted keywords and phrases generated
from our original search strategy. The first 100 hits of
each search will be screened by title and abstract. If a
high proportion of the first 100 hits (≥ 10%) can poten-
tially be included, then a further 100 hits will be
searched continuing until the next 100 hits contain ≤
10% of potentially includable hits. If the initial search
produces fewer than 100 hits, then all hits will be
searched.
See Appendix 2 for sample grey literature search
strategy.
Study records
Data management
Exported citations from traditional databases will be en-
tered and de-duplicated into EndNote X8 (Clarivate An-
alytics). Grey literature results will be manually entered
or, where available, captured through a browser-based
citation management plug-in (such as Zotero [https://
www.zotero.org/]) then imported into EndNote. Using a
structured and piloted data extraction form, we will ex-
tract relevant outcome data, study characteristics, and
participant characteristics from each included paper.
Data will be extracted by one reviewer and checked by
another.
Selection process
Indexed and academic databases
Two waves of study selection will be undertaken. Titles
and abstracts will be screened by two reviewers inde-
pendently and disagreements resolved by discussion or,
Thompson et al. Systematic Reviews  (2018) 7:9 Page 6 of 15
where necessary, a third reviewer (title and abstract
screening will be conducted using Rayyan software
(QCRI; Doha, Qatar; https://rayyan.qcri.org/)). Two ini-
tial subsets of 500 results will be screened by two re-
viewers and inclusion and exclusion discrepancies
discussed following each in order to ensure good agree-
ment between reviewers. Following this, a set of 1000
will be completed and discussed before the remaining
results being screened independently by two reviewers.
This will help ensure reliable and consistent screening.
Full texts will be obtained for studies appearing to meet
the criteria above and screened by two reviewers (each
paper reviewed by one member of the team and checked
by another). Disagreements are resolved through discus-
sion and a third reviewer (AT). RK will be consulted in
relation to uncertainty over economic evaluations arising
from the two independent reviewers.
The same process will apply for grey literature
searching.
Appraisal of studies (quality and bias)
We will evaluate risk of bias at the level of outcomes.
Randomised controlled trials will be assessed for quality
and risk of bias using the Cochrane Risk of Bias Tool
[49], and non-randomised studies will be assessed using
the ROBINS-I [50]. Any economic evaluations will be
assessed for study quality using the Consolidated Health
Economics Evaluation Reporting Standards (CHEERS)
[51] checklist. Qualitative studies will be assessed for
quality using a ten-item checklist for qualitative studies
developed and published by the Critical Skills Appraisal
Programme (CASP) [52] which focuses on rigour, cred-
ibility, and relevance without being overly restrictive.
CASP will be used to appraise studies but not to exclude
any studies.
Data synthesis
Data synthesis will be adapted from the multilevel ap-
proach as suggested in the Cochrane Handbook of Sys-
tematic Reviews: Quantitative and qualitative evidence
will be reviewed separately and then combined into an
overall narrative synthesis. A narrative synthesis of ser-
vice evaluations and economic data will be integrated
into the main synthesis to aid in contextualising the re-
sults in terms of implementation.
Quantitative studies (analysis A)
Where data allow (e.g. data on the same outcome from
at least two studies of similar design, intervention, and
population), we will conduct a meta-analysis to estimate
the overall effect and consistency of the intervention ef-
fect across studies. As the population and setting of
studies are likely to be different, we will use a random-
effects model to obtain the summary result as an
estimate of the average intervention effect rather than
the common effect estimated from a fixed effects model
[53]. Where possible, we will create and examine funnel
plots for the association between study size and esti-
mated effect size, which could be due to publication
bias. Where possible, we will explore the extent to which
the intervention characteristics, study setting (country,
socioeconomic status, healthcare system), and partici-
pant characteristics moderate the effect of interven-
tions, through conducting meta-regressions or
subgroup analyses.
We will not combine data from non-randomised trials
which used different study designs, or data from rando-
mised trials and non-randomised trials, in a meta-
analysis, as the estimated intervention effects from dif-
ferent study designs can be influenced by different
sources of bias and/or increased heterogeneity [45]. In
those cases, where suitable numerical data are not avail-
able for pooling, or if pooling is considered inappropri-
ate, we will use other approaches to provide a systematic
summary of the studies, including tabulation, transform-
ation of data into common rubric (e.g. days abstinent),
groupings and clusters (e.g. different population to as-
sess influence of country, age, socioeconomic status,
type/intensity of intervention, setting), and textual de-
scriptions including a detailed narrative synthesis [54].
Qualitative studies (analysis B)
The qualitative synthesis aims to describe qualitative
data relating to the acceptability, feasibility, mechanisms,
mediators, and moderators of physical activity in relation
to alcohol and/or substance use. Data on the develop-
ment, design, methods, and the populations involved will
be extracted from qualitative studies using a bespoke
data extraction form. The complete “findings” or “re-
sults” sections of the qualitative study reports will be
exported into NVivo 10 (QSR International Pty Ltd.).
Each section will then be read and re-read by two re-
viewers, in conjunction with the data extraction form, to
enable the reviewers to familiarise themselves with the
study findings in the context of the study population,
setting, and methods. Adopting a thematic analysis ap-
proach, reviewers will code and identify emergent
themes and concepts independently (extracting associ-
ated quotes). The reviewers will come together to con-
solidate the findings into one summary of overarching
themes. Associated quotes will be presented to support
the identified themes. The review team will then draw
out implications of the themes for policy and practice.
Service evaluations (analysis C)
Service evaluations will be considered separately from
the academic literature, and through a thematic synthe-
sis approach will be summarised to help understand
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contextual and implementation issues surrounding the
delivery of PA for alcohol and/or substance use. It will
also be used, where possible, to contextualise data from
the academic literature within the UK context to aid
with the final narrative synthesis.
Economic evaluations (analysis D)
The review of resource use, costs, relative effectiveness
and cost-effectiveness will include a descriptive summary
of the (economic) study questions, methods, and results,
culminating in a narrative synthesis. Since the purpose
of our review is to provide clear and concise information
on the existing economic evidence base, we will also
consider partial economic evaluations. These may in-
clude cost comparisons, as well as studies with an exclu-
sive focus on relative benefits, i.e. studies that discuss
willingness to pay or preference-based outcome mea-
sures. Summary tables will not be limited to description
of economic outcomes alone and will include all relevant
information integral to the economic study. We will ex-
tract detail on analytic methods, study perspective, price
year, country, currency, and time horizon with further
extraction fields informed by section headings within the
CHEERS [51] checklist. Since we do not anticipate a
substantial amount of economic literature, our methods
may focus on translating findings from the review for
the purposes of dissemination and stakeholder input. All
types of comparative economic study design, including
decision-analytic modelling approaches, will be included.
Narrative synthesis
The analysis of the quantitative (analysis A), qualitative
(analysis B), service evaluation (analysis C), and eco-
nomic (analysis D) data will be integrated to develop a
narrative synthesis. This will be summarised for dissem-
ination to PPI groups and key stakeholders and used as
a basis for generating critical input to help understand
the implications of the findings for different groups.
Measures of intervention effects (quantitative data)
Dichotomous data
We will present dichotomous data as risk ratios with
their associated 95% confidence intervals (CI).
Continuous data
For continuous data, we will calculate the mean differ-
ences (MD) for outcomes measured by the same scale or
the standardised mean differences (SMD) for outcomes
measured by different scales and present both with a
95% CI.
Outcomes at multiple time points
If outcomes were collected at multiple time points, we
will attempt to present a summary effect over all time
points. If this is not possible, we will choose one time
point that is the most appropriate one and report the
corresponding summary effect at that time point.
Unit of analysis issues
Cluster randomised trials are susceptible to unit-of-
analysis errors if the analysis was performed at the level
of the individual without accounting for the clustering in
the data. If the clustering effect has been accounted for
in the analysis, the estimated intervention effect will be
obtained from the reported summary data. If the cluster-
ing effect has not been accounted for, we will conduct
an approximate analysis using the intra-cluster correl-
ation coefficient (ICC), as suggested in the current
guidelines [45]. If the ICC is available in the study re-
ports or can be obtained from similar studies, we will
use the available ICC to calculate the inflated standard
error or effective sample size to account for the cluster-
ing effect. If a relevant ICC is not available, we will re-
port the estimated intervention effect as presented but
report the issue of unit of analysis error.
Dealing with missing data
If a study did not provide the summary data of the inter-
vention effects, we will contact the study authors on one
occasion to request these data. Where individual-level
data are missing due to participant dropout, we will con-
duct available case analyses and record any issues of
missing data in the ‘Risk of bias’ table. If standard error
is available but standard deviations are not reported in a
study, we will estimate the standard deviation from the
reported standard error and the sample size. We will cal-
culate the effect estimate and its standard deviation if
these are not reported, but the 95% CI is reported.
Assessment of statistical heterogeneity
We will assess statistical heterogeneity by inspection of
forest plots, and by formal statistical tests of homogen-
eity (Chi-squared), measures of inconsistency (I2) [55],
and between-study variance (tau2). We interpret the
level of heterogeneity as follows: the heterogeneity is not
important if I2 is lower than 40%; there is moderate het-
erogeneity if I2 is between 30 and 50%; and there is sub-
stantial or considerable heterogeneity if I2 is greater than
50% [45]. If substantial heterogeneity is identified among
studies, we will explore the potential causes of hetero-
geneity by conducting subgroup analyses or meta-
regression where possible.
Assessment of reporting biases
We will examine the possibility of publication bias and
other small study effects using funnel plots of the inter-
vention effect estimates against the inverse of their
standard errors and test funnel plot asymmetry using
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Egger’s method [56] when there is a sufficient number of
studies. This is considered at least ten, as a smaller num-
ber would leave the power of the test too low to distin-
guish chance from real symmetry.
Sensitivity analysis
We will conduct a sensitivity analysis based on quality
indicators thought to be significant by the review team.
Studies thought to be at high risk of bias due to specific
quality indicators (e.g. lack of randomisation) will be re-
moved to ascertain their effect on the estimated overall
effect. We also intend to conduct a sensitivity analysis
using fixed-effect models.
Confidence in cumulative evidence
The quality of evidence will be assessed using domains
of the Grading of Recommendations, Assessment, De-
velopment, and Evaluation (GRADE) [57] guidelines.
Strength of evidence will be judged as ‘high’ (further re-
search is very unlikely to change confidence in our find-
ings), ‘moderate’ (further research is likely to have an
important impact on our findings), ‘low’ (further research
is likely to have an important impact and change our
findings), ‘very low’ (further research is needed to draw
any conclusions).
External validity/generalisability
We will explore generalisability at the study level and on
the level of the aggregated evidence.
We will collect the following data from each study: de-
tails of the intervention, fidelity of the intervention and
adherence to it (this includes who delivers the interven-
tion), rationale supporting the choice of outcome mea-
sures, and setting in which the study was conducted
(country, socioeconomic status of the setting, healthcare
system). Depending on the type of available data, we will
analyse them using subgroup analyses, meta-regression,
or contextualise it through narrative synthesis.
Advisory groups
We will establish advisory groups: consisting of aca-
demics, service providers, and service users. These
groups will offer varying perspectives on pertinent issues
arising and will provide input into different aspects of
the review.
The academic group will be asked to provide a critical
voice on the interpretation of findings, to ensure no as-
pect has been overlooked, and to aid in establishing net-
works for finding data and disseminating results.
The service provider group will offer insight into the
UK context in which alcohol and substance use exists,
what the commissioning landscape looks like, current
and future reach and structure of services and interven-
tions, contextualise findings to the current UK climate,
and to aid in dissemination and implementation of
results.
The service user group will offer input into what out-
comes we should be searching for, approaches to pro-
mote physical activity (i.e. sport, exercise, and daily
activity) would be most acceptable to people; and in
what other ways could support services (who, where,
when) be set up to maximise the reach and effectiveness
for promoting physical activity for the prevention, reduc-
tion, and treatment of alcohol and substance use.
To maximise the impact of stakeholder, public, and pa-
tient involvement, we will develop a user-friendly synthesis
of the findings and nature of interventions and their appar-
ent strengths and weaknesses working with the advisory
groups. Once a user-friendly synthesis has been generated,
it will be disseminated to key stakeholder groups and indi-
viduals and their feedback and input will be used to gain
further insights into what the evidence suggests and where
any gaps may exist. Specifically, people will represent differ-
ent stages of addiction, including those who are occasional
users at risk of progressing to regular users of alcohol and/
or substance use, non-treatment seekers who wish to min-
imise harm, and those currently receiving treatment or who
are in recovery. This synthesis will then be disseminated to
key stakeholder groups and individuals and used as the
basis for several group and individual meetings to gain fur-
ther input into what the evidence suggests and where any
gaps may exist.
Dissemination and intended publications
Upon completion of the review, we will develop a sum-
mary of key findings of the review of literature, a sum-
mary of the PPI assessment of the findings, and issues
associated with service development and delivery
highlighted by policy makers and service managers. We
will present the findings at relevant academic confer-
ences and a website that will be established to summar-
ise the findings and implications, with links to access a
final report. We intend also to organise a one-day con-
ference to which key stakeholders, advisory board mem-
bers, and any interested party will be invited. In addition
to a final report, we anticipate submitting articles for
publication in peer-reviewed open access journals.
We will also disseminate the findings by phone or
Skype to Directors of Public Health (or leads for alcohol
and substance misuse) and managers of organisations
across the UK who do or could involve physically active
interventions to gain a further insight into the issues as-
sociated with securing the necessary resources.
Discussion
The scope and methods for this review have been
strongly influenced by both service provider and user
perspectives throughout the development of the
Thompson et al. Systematic Reviews  (2018) 7:9 Page 9 of 15
application and this protocol. The review will generate im-
portant and timely information to inform the provision of
services for alcohol and substance use. Through the con-
tinued engagement with stakeholders, the information
produced will have relevance across a variety of settings in
addressing the prevention, reduction, and treatment of al-
cohol and/or substance use throughout the UK. A wide
variety of dissemination plans will ensure the information
is accessed by the most relevant services, as well as aiding
to direct future research efforts.
The size and scope of the review, whilst challenging, will
ensure that the information brought together in this review
will be as encompassing as possible and will provide all the
necessary information about what we know about what
works, for who, when, where, and how in an accessible and
appropriate way. Information generated from this review
will have the potential to directly impact on provision in sev-
eral domains and address (where possible) issues of accept-
ability, feasibility, implementation, and cost-effectiveness.
Appendix 1
Sample search strategy
Databases to be searched
To be conducted by AW.
 MEDLINE (Ovid)
 MEDLINE (PubMed) Note: supplementary search only
 Embase (Ovid)
 PsycINFO (Ovid)
 Cochrane Library (Wiley)
 International Bibliography of the Social Sciences
(ProQuest)
 Web of Science
 CINAHL (Ebsco)
 AMED (EBSCO)
 Social Policy and Practice (Ovid)
 Applied Social Sciences Index and Abstracts
(ProQuest)
 ProQuest Dissertations & Theses (ProQuest)
 SocIndex (Ebsco)
 SportDiscus (Ebsco)
Sample database search to be translated into the
databases above
Database: MEDLINE
Host: Ovid
Data parameters: Ovid MEDLINE(R) Epub Ahead of
Print, In-Process & Other Non-Indexed Citations, Ovid
MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to
Present
Date searches: 2-jun-17
Searcher: AW
Hits: 12,860
Strategy:
# Searches Results
1 exp exercise/ 157,603
2 exp exercise therapy/ 41,209
3 exp exercise movement techniques/ 6736
4 sedentary lifestyle/ 5870
5 exercis*.ti,ab,kw. 255,603
6 Fitness.ti,ab,kw. 57,641
7 sport*.ti,ab,kw. 61,127
8 isometric.ti,ab,kw. 29,699
9 yoga.ti,ab,kw. 3404
10 tai chi.ti,ab,kw. 1308
11 qigong.ti,ab,kw. 519
12 walk*.ti,ab,kw. 96,513
13 Jog*.ti,ab,kw. 2103
14 (weight lifting or weightlifting).ti,ab,kw. 1195
15 sedentary.ti,ab,kw. 24,682
16 pedometer*.ti,ab,kw. 2223
17 aerobic*.ti,ab,kw. 74,000
18 (physical adj1 (train* or program* or activit* or inactivity or
fitness or conditioning)).ti,ab,kw.
100,132
19 ((resistance or strength or endurance or weight) adj2
train*).ti,ab,kw.
17,368
20 or/1-19 [ physical activity terms ] 630,395
21 Substance-Related Disorders/ 88,741
22 Alcohol-Related Disorders/ 4588
23 Alcohol-Induced Disorders/ 251
24 Alcoholic Intoxication/ 12,082
25 Alcoholism/ 72,144
26 Binge Drinking/ 1060
27 Amphetamine-Related Disorders/ 2676
28 Cocaine-Related Disorders/ 7413
29 Drug Overdose/ 9375
30 Inhalant Abuse/ 176
31 Marijuana Abuse/ 5487
32 Opioid-Related Disorders/ 10,773
33 Heroin Dependence/ 8695
34 Morphine Dependence/ 3356
35 Phencyclidine Abuse/ 238
36 Psychoses, Substance-Induced/ 5159
37 Substance Abuse, Intravenous/ 13,950
38 Substance Withdrawal Syndrome/ 20,489
39 Alcohol Withdrawal Delirium/ 1900
40 Alcohol Withdrawal Seizures/ 244
41 alcoholics/ 788
42 drug users/ 2194
43 underage drinking/ 293
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(Continued)
# Searches Results
44 Alcohol Drinking in College/ 200
45 designer drugs/ 1294
46 exp street drugs/ 10,924
47 prescription drug misuse/ 1072
48 Alcohol Abstinence/ 350
49 Alcohol Drinking/ 60,264
50 ((alcohol or ethanol or drug* or inhal* or inject* or
substance) adj2 (abstinence or abstain or abuse or
craving* or dependenc* or illegal or illicit or misuse or
overdos* or prevent* or recovery or recreational or use* or
withdrawal)).ti,ab,kw.
243,666
51 (prescription adj2 (abuse or craving* or dependenc* or
illegal or illicit or misuse or nonmedical or non-medical or
overdos* or recreational or withdrawal)).ti,ab,kw.
1963
52 (hard* adj1 drug*).ti,ab,kw. 550
53 (withdrawal adj2 (symptom* or syndrome*)).ti,ab,kw. 8682
54 hazardous drinking.ti,ab,kw. 830
55 harmful drinking.ti,ab,kw. 355
56 binge drinking.ti,ab,kw. 3839
57 alcohol-related.ti,ab,kw. 10,715
58 alcoholics.ti,ab,kw. 14,313
59 alcoholism.ti,ab,kw. 27,726
60 alcohol intoxication.ti,ab,kw. 2631
61 addict*.ti,ab,kw. 53,792
62 drug seeking.ti,ab,kw. 2296
63 polydrug.ti,ab,kw. 1348
64 bath salt*.ti,ab,kw. 308
65 cannabis.ti,ab,kw. 12,221
66 cocaine.ti,ab,kw. 34,890
67 coke.ti,ab,kw. 1657
68 crack.ti,ab,kw. 7033
69 designer drug*.ti,ab,kw. 1231
70 dextroamphetamine.ti,ab,kw. 640
71 ecstasy.ti,ab,kw. 3471
72 hallucinogen*.ti,ab,kw. 3180
73 hashish.ti,ab,kw. 559
74 heroin.ti,ab,kw. 12,723
75 hookah.ti,ab,kw. 495
76 legal high*.ti,ab,kw. 395
77 lsd.ti,ab,kw. 4631
78 lysergic acid.ti,ab,kw. 1889
79 marijuana.ti,ab,kw. 10,943
80 mdma.ti,ab,kw. 3715
81 meth.ti,ab,kw. 7061
82 methamphetamine*.ti,ab,kw. 9984
83 methylenedioxyamphetamine.ti,ab,kw. 569
(Continued)
# Searches Results
84 opiate*.ti,ab,kw. 23,806
85 opioid*.ti,ab,kw. 71,719
86 opium.ti,ab,kw. 2207
87 phencyclidine*.ti,ab,kw. 4369
88 psychedelic*.ti,ab,kw. 628
89 psychoactive.ti,ab,kw. 8018
90 psychostimulant*.ti,ab,kw. 5544
91 street drug*.ti,ab,kw. 582
92 volatile solvent*.ti,ab,kw. 356
93 water pipe*.ti,ab,kw. 656
94 ((alprazolam or amobarb* or amphetamine* or analgesic*
or anthramycin or anxiolytic* or barbiturate* or
benzodiazepine* or bromazepam or buprenorphine or
chlordiazepoxide or clonazepam or clorazepate or
cannabinoid* or codeine or demerol or devazepide or
diazepam or dilaudid or dronabinol or duloxetine or
endocannabinoid* or ephedrine or estazolam or estradiol
or fentanyl or flumazenil or flunitrazepam or flurazepam or
gabapentin or haloperidol or hydrocodone or
hydromorphone or hypnotics or ketamine* or lorazepam
or medazepam or meperidine or methadone or
methylphenidate or midazolam or morphine or narcotic*
or nitrazepam or oxazepam or oxycodone or oxycontin*
or pentobarb* or pentobarbital or percocet or
phenobarbital or piperazine* or pirenzepine or prazepam
or pregabalin or propranolol or relaxant* or ritalin or
secobarb* or sedative* or sleeping pill* or stimulant* or
temazepam or tetrahydrocannabinol or tramadol or
tramadol or tranquilizer* or triazolam or valium or vicodin
or zolpidem) adj2 (abstinence or abstain or abuse or
craving* or dependenc* or illegal or illicit or misuse or
nonmedical or non-medical or nonprescription or non-
prescription or overdose or prevent* or recovery or recre-
ational or use* or withdrawal)).ti,ab,kw.
38,251
95 or/21-94 [ substance abuse terms ] 591,486
96 20 and 95 15,766
97 96 not (exp animals/ not (exp animals/ and humans/))
[remove animal studies]
14,357
98 limit 97 to (english language and yr=“1975 -Current”) 12,860
Appendix 2
Grey literature search strategy
Search engines
Strategy 1
 Google
 Google Scholar
** Note: prior to commencing search, log out of any
google services (eg gmail) AND use browser’s “incognito”
mode to ensure depersonalised results are shown.
Thompson et al. Systematic Reviews  (2018) 7:9 Page 11 of 15
**Note 2: copy and paste the entire search query into
google and google scholar *exactly as written*. Do not add
extra spaces, etc.
Two search queries, both to be used in both google
AND google scholar:
1 substance|alcohol|drug|opioidabuse|misuse|withdrawal|abstinence
|addict|craving|dependency|illegal|illicit|overdose|prevention|use|user|
recreational|recovery exercise|"physical activity"|fitness|sedentary
2 substance|alcohol|drug|opioid abuse|misuse|withdrawal|
abstinence|addict|craving|dependency|illegal|illicit|overdose|
prevention|use|user|recreational|recovery exercise|"physical activity"|
fitness|sedentary UK|"United Kingdom"|England|Britain|NHS
Grey lit databases
Strategy 1:
 Scottish Addiction Studies online library
 HRB National Drugs Library (use “all fields” search)
 NIDA International Drug Abuse Research Abstract
Database (press enter to search; press enter with
blank search to see total contents of the database)
Searches for the above databases:
**Note: Each of these searches use “physical activity”
related terminology because the databases above are drug
and alcohol related. Feel free to search for other relevant
terminology as needed and record results in Excel.
1 exercise
2 "physical activity"
3 fitness
4 sport
5 sedentary
Strategy 2:
 British Library EThOS
 Tufts CEA Registry (Basic search –> Search for
“articles”)
Searches for the above databases:
**Note: Each of these searches use a “physical activity”
related term combined with a drug/alcohol misuse term.
Feel free to search for other relevant combinations as
needed and record results in Excel.
1 drugs AND exercise
2 opioids AND exercise
(Continued)
3 substance AND exercise
4 alcohol AND exercise
5 drugs AND "physical activity"
6 opioids AND "physical activity"
7 substance AND "physical activity"
8 alcohol AND "physical activity"
Strategy 3:
 NHS Evidence
Searches for the above database:
Note: Searches are split into two because of character
limits of NHS Evidence search box
1 (substance OR alcohol OR drug OR opioid) AND (abuse OR
misuse OR withdrawal OR abstinence OR addict OR craving OR
dependency OR illegal OR illicit OR overdose OR prevention OR
user OR recreational OR recovery) AND (exercise OR "physical
activity")Select: "primary research" in sidebar
2 (substance OR alcohol OR drug OR opioid) AND (abuse OR
misuse OR withdrawal OR abstinence OR addict OR craving OR
dependency OR illegal OR illicit OR overdose OR prevention
OR user OR recreational OR recovery) AND (fitness OR
sedentary)Select: "primary research" in sidebar
Strategy 4:
 Open Grey
Search for the above database:
1 discipline:(05* OR 06*) lang:"en" (substance OR alcohol OR drug
OR opioid) AND (abuse OR misuse OR withdrawal OR
abstinence OR addict OR craving OR dependency OR illegal OR
illicit OR overdose OR prevention OR use OR user OR
recreational OR recovery) AND (exercise OR "physical activity"
OR fitness OR sedentary)
Strategy 5:
 Database of promoting health effectiveness reviews
(DoPHER) (Select “free text” radio button)
Search for the above database:
1 (substance OR alcohol OR drug OR opioid) AND (abuse OR
misuse OR withdrawal OR abstinence OR addict OR craving OR
dependency OR illegal OR illicit OR overdose OR prevention
OR use OR user OR recreational OR recovery) AND (exercise OR
"physical activity" OR fitness OR sedentary)
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Strategy 6:
 Big Lottery Fund Database https://
www.biglotteryfund.org.uk/funding/search-past-
grants?page=0
Search for the above database:
1 Download all items from the database and create smart group in
EndNote (n = 216,850)Any field ➔ word begins with ➔ substance*;
alcohol*; drug*; opioid*; addict*ANDAny field ➔ word begins with ➔
exercise*; fitness; "physical activity"; fitness; sedentary; sport*= 263
hits
Strategy 7:
To be conducted by AW.
 Proquest Dissertations and Theses
Using modified search strategies from the traditional
database searches.
Grey lit searching procedures
Part 1: Database/ search engines
1. Conduct each search in each database.
2. For each search, record:
a. Date
b. Database and search query (in full)
c. Total number of hits (if available), or estimate if
not.
d. Number of potentially relevant citations from
search (not full websites, just papers/articles/etc.)
3. For each, screen first 100 hits (by title and abstract).
If above 10% are relevant, screen next 100 hits, and
so forth.
4. For each potentially relevant hit:
a. If the hit is an article or paper, add to reference
management system. Ensure at a minimum that
title and URL are captured.
b. If the hit is a website, add to excel spreadsheet for
follow-up later (see below).
5. From all potentially relevant hits downloaded to
reference management software, full-text screening
of grey literature to be conducted by two people
(half of results to be screened by each, with results
checked by second person).
Part 2: Websites
1. For each website identified as potentially relevant
(by experts, google searches, or any other sources),
list website in Excel spreadsheet and conduct a
search for relevant articles/papers.
2. For each website, search strategies might include
any of the below, as necessary:
a. Handsearching of menus
b. Use of search bars with relevant terminology
from searches above
c. Use of Google to search within the website, such
as:
i. “substance abuse” exercise site:website.com
d. Use of Google to search within the website to
find PDFs, such as:
i. “substance abuse” exercise site:website.com
filetype:pdf
3. For each search, record in Excel:
a. Date
b. Website, including URL
c. Process used (e.g. search bar, hand searching,
which menus used, targeted google site search,
etc.)
d. Number of potentially relevant hits from each
website.
4. For each hit, add to reference management system
(it may be worthwhile to use a browser plug-in, such
as from Zotero or Mendeley to semi-automate the
process).
5. From all potentially relevant hits downloaded to
reference management software, full text screening
of grey literature to be conducted by two people
(half of results to be screened by each, with results
checked by second person).
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